Tickr
Home Explore Daily Brief Market Watchlists Portfolio
Research
Catalysts Signal Factory Screener Market News Event Calendar Valuation Plot Heat Map Top Investors Industry Trends Options
AI Assistant Notifications Account
Cartesian Therapeutics, Inc. logo

Cartesian Therapeutics, Inc. (RNAC) Stock Ticker

NASDAQ: RNAC · Healthcare · Biotechnology
$7.41-2.76%
USD · as of 2026-09-28 · market cap $217.7M
Open RNAC in TickrDownload for iPhone

RNAC right now

Options expect by Oct 6±8.4%
Options expect by Oct 29±17.4%
Priced in for Nov 5 earnings±19.3%
IV rank (30-day)51% · fair
From Tickr's live models · 2026-09-29. Not investment advice.

Market factors today

Tickr 500 vs S&P 500+0.49%+1.0% MTD
Momentum L/S+1.35%+15.1% MTD
High-beta momo L/S+1.46%+22.2% MTD
Rate sensitivity L/S+1.91%+6.9% MTD
Oil sensitivity L/S-2.54%-5.3% MTD
Unprofitable tech-1.43%+3.7% MTD

Unlock the full RNAC picture

🔒 Implied move chart & probabilities
🔒 Live options flow
🔒 AI analysis & chat on RNAC
🔒 Catalysts & earnings
🔒 Strategy Lab
🔒 Financials & estimates
Start your 7-day free trial

About Cartesian Therapeutics, Inc.

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.

RNAC stock facts

Ticker symbolRNAC
ExchangeNASDAQ
SectorHealthcare
IndustryBiotechnology
Market cap$217.7M
CEOCarsten Brunn
Employees75
HeadquartersFrederick, MD, US
IPO date2016-06-22
Websitecartesiantherapeutics.com

What you can see for RNAC on Tickr

Live RNAC price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the RNAC report.

Rankings

Largest Healthcare companiesLargest companies by market cap

FAQ

What is the ticker symbol for Cartesian Therapeutics, Inc.?

The ticker symbol for Cartesian Therapeutics, Inc. is RNAC, listed on the NASDAQ.

What is RNAC?

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune…

HomeExploreMarketLists
All pages